Twist Bioscience Announces Presentations and User Group Meeting at PEGS Boston 2019

April 1, 2019 |

2 min read

Aaron Sato, Ph.D., Chief Scientific Officer of Twist Biopharma, to Deliver Keynote Address

SAN FRANCISCO--(BUSINESS WIRE)-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced five presentations at PEGS (The Essential Protein Engineering Summit) taking place April 8-12, 2019 at the Seaport World Trade Center in Boston. The presentations include an overview of Twist Biopharma as well as proof-of-concept data for its GPCR library and antibody optimization solutions from Aaron Sato, Ph.D., Chief Scientific Officer of Twist Biopharma, and four poster presentations.

The presentations will occur on Monday, April 8^th. The company will also host a User Group Meeting on Wednesday, April 10^th at 6:45 pm ET. Full event information can be found here.

The details for the presentations are as follows:

Presentation at PEGS

Date: Monday, April 8, 2019
Time: 1:50 pm - 2:20 pm
Location: Auditorium
Speaker: Aaron Sato, Ph.D., CSO, Twist Biopharma
Talk Title: Synthetic DNA Technologies Enable Antibody Discovery and Optimization

Poster Presentations

Date: Monday, April 8, 2019
Time: 5:40 pm – 7:15 pm
Location: Commonwealth Hall
Poster Session: A

Poster Number: A103
Precision Synthesis of Variant Libraries Enables Comprehensive Interrogation of Single Site Variant Space

Poster Number: A104
A High-Throughput Platform to Develop Highly Potent and Functional Antibodies Against G-Protein Coupled Receptors

Poster Number: A105
Twist Bioscience’s Silicon-Based DNA Synthesis Platform Enables the Construction of Focused Variant Libraries with Unprecedented Precision

Poster Number: A106
Rapid Optimization and Humanization of an Anti-PD1 Antibody

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190401005252/en/

Contacts

Twist Investor Contact:
Argot Partners
Maeve Conneighton
212-600-1902
maeve@argotpartners.com

Twist Media Contact:
Angela Bitting
925-202-6211
media@twistbioscience.com

Source: Twist Bioscience Corporation

View this news release online at:
http://www.businesswire.com/news/home/20190401005252/en

Events